Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  68 results for ""Antineoplastic Agents, Immunological""

Your Filters

Publication : jama oncology
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Editorial & Opinion

Considerations in Meta-Analysis of Immunotherapy for Advanced Cancers Other Than Melanoma.

  • Authors : Pang H; Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing, China.; Sun H

Subjects: Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/therapeutic use ; Melanoma*/Melanoma*/Melanoma*/drug therapy ; Skin Neoplasms*

  • Source: JAMA oncology [JAMA Oncol] 2024 Apr 01; Vol. 10 (4), pp. 535-536.Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Editorial & Opinion

Considerations in Meta-Analysis of Immunotherapy for Advanced Cancers Other Than Melanoma-Reply.

  • Authors : Shenoy NK; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.; Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Subjects: Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/therapeutic use ; Melanoma*/Melanoma*/Melanoma*/drug therapy ; Skin Neoplasms*

  • Source: JAMA oncology [JAMA Oncol] 2024 Apr 01; Vol. 10 (4), pp. 536.Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Association of Corticosteroids With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab.

  • Authors : Lefort F; Medical Oncology, CHU Bordeaux-Hopital St André, Bordeaux, France.; Dalban C

Subjects: Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/pathology ; Kidney Neoplasms*/Kidney Neoplasms*/Kidney Neoplasms*/pathology ; Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/adverse effects

  • Source: JAMA oncology [JAMA Oncol] 2023 Sep 01; Vol. 9 (9), pp. 1295-1298.Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Editorial & Opinion

Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade.

  • Authors : Aslan V; Department of Medical Oncology, Gazi University, Ankara, Turkey.; Yazici O

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology

  • Source: JAMA oncology [JAMA Oncol] 2023 Apr 01; Vol. 9 (4), pp. 570.Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Editorial & Opinion

Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade-Reply.

  • Authors : Ricciuti B; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Wang X

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology

  • Source: JAMA oncology [JAMA Oncol] 2023 Apr 01; Vol. 9 (4), pp. 570-571.Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Editorial & Opinion

Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade.

  • Authors : Zhang X; Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, China.; Zhang L

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology

  • Source: JAMA oncology [JAMA Oncol] 2023 Apr 01; Vol. 9 (4), pp. 569-570.Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Neoadjuvant Immunotherapy for Patients With Non-Small Cell Lung Cancer-Is a New Era Coming?

  • Authors : Zhang B; Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.; Zhong H

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy ; Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/adverse effects

  • Source: JAMA oncology [JAMA Oncol] 2023 Mar 01; Vol. 9 (3), pp. 301-302.Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.

  • Authors : Saba NF; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.; Winship Cancer Institute, Emory University, Atlanta, Georgia.

Subjects: Nivolumab*/Nivolumab*/Nivolumab*/therapeutic use ; Nivolumab*/Nivolumab*/Nivolumab*/adverse effects ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/radiotherapy

  • Source: JAMA oncology [JAMA Oncol] 2024 Jul 01; Vol. 10 (7), pp. 896-904.Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Unveiling the Untapped Potential of Antibody Drug Conjugates in Precision Oncology.

  • Authors : Trapani D; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Subjects: Precision Medicine* ; Immunoconjugates*/Immunoconjugates*/Immunoconjugates*/therapeutic use ; Immunoconjugates*/Immunoconjugates*/Immunoconjugates*/adverse effects

  • Source: JAMA oncology [JAMA Oncol] 2024 May 01; Vol. 10 (5), pp. 563-564.Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.

  • Authors : Goldstein DA; Davidoff Center, Rabin Medical Center, Petach Tikvah, Israel.; Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill.

Subjects: Body Weight* ; COVID-19* ; Delivery of Health Care*

  • Source: JAMA oncology [JAMA Oncol] 2020 Nov 01; Vol. 6 (11), pp. 1694-1695.Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  68 results for ""Antineoplastic Agents, Immunological""